Modular Medical, Inc.: Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump

Modular Medical, Inc. (NASDAQ:MODD) announced a contract with a national U.S. pharmacy benefit manager (PBM), expanding access to its Pivot tubeless patch pump for diabetes patients. The company believes this partnership will broaden patient access and validate its insulin delivery system. Modular Medical aims to simplify diabetes management with its innovative medical device.

Original reporting
Published Sep 4, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MODD
Bullish
medium confidence
Mentioned
$MODD
Relevance
5/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$MODDBullishLow
01

Why it matters

The PBM contract could improve formulary placement and patient access, supporting revenue growth, but the lack of disclosed financial terms tempers expectations.

02

Market read

A new distribution agreement for a diabetes device may boost Modular Medical's outlook, though impact size is uncertain.

03

What to watch

Potential reimbursement negotiations, competitive response from established pump makers, and execution risk of scaling manufacturing.

Relevance 5/10Novelty 6/10Timing: today

Background

Modular Medical is a commercial‑stage medical‑device company focused on insulin delivery technologies. The Pivot tubeless patch pump is its flagship product.

Company-level read

Ticker impact

$MODDBullishMedium confidence
Context

Modular Medical announced a contract with a national U.S. pharmacy benefit manager to make its Pivot tubeless patch pump available through the PBM.

Expected impact

Modular Medical may see modest upside pressure as market participants price in broader patient access.

Evidence & confidence

The announcement is a fresh commercial milestone, but no financial terms were disclosed, limiting the magnitude of the expected impact.

Market effects

The deal highlights growing importance of PBM partnerships for diabetes device manufacturers.

U.S. diabetes device market may see incremental demand as insurers adopt the Pivot pump.

Limited; the news is specific to the U.S. market and does not affect global peers significantly.

Counterpoint

Without disclosed pricing or volume, the contract may not materially move the stock and could be over‑hyped.

Key entities

  • Modular Medical, Inc.

    Issuer of the Pivot tubeless patch pump.

  • National U.S. Pharmacy Benefit Manager

    Unnamed large PBM that will carry the Pivot pump.

Related articles

$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

$INTCMed

Intel signs first outside customer for 18A process as yields reach 70%

Intel announced its first external customer for the 18A manufacturing process, with yields reaching 70%. CEO Lip-Bu Tan highlighted the improvement from previous 'horrible' levels. The 18A node combines RibbonFET and PowerVia technologies. Intel also partnered with Microsoft for Azure infrastructure using EMIB packaging. The company aims to release internal 14A products by late 2027, with external customers expected in 2028-2029.

$NVDAMed

Nvidia's $332 Billion AI Cloud Bet Has a Second Act

Nvidia (NVDA) announced up to $32B in commitments for neocloud agreements, aiding cloud providers in expanding AI computing power. Revenue will come from hardware sales and potential revenue sharing. Key milestones include securing funding and operational capacity, with $6B in fiscal 2028, $7B in 2029, and $8B from 2032 onwards.

$KNSAMed

Top pharma stock to watch: TD Cowen’s pick

TD Cowen identifies Kiniksa Pharmaceuticals (KNSA) as a top pick in the pharma sector, citing strong commercial momentum for Arcalyst and potential value from pipeline candidates. The firm set a $115 price target, noting underpenetrated markets and conservative revenue growth projections. KPL-387, a wholly owned drug, could add $6 to earnings per share by 2027.